AN2 Therapeutics, Inc. (ANTX) earnings
ANTX earnings moved a median of -2.39% by the close. Quarterly and annual ANTX reports and results, each read against the price at its own news timestamp. Back to the ANTX overview →
22 measured ANTX earnings events.
Where these ANTX earnings landedvs 20 measured ANTX earnings reactions
| Middle 50% of ANTX earnings reactions | -3.43% to +2.16% |
|---|---|
| Median reaction (to close) | -2.39% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ANTX earnings events with a measured close landed between -3.43% and +2.16%; 30% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights | Press release | +10.92% | +3.12% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +10.92% | +3.12% | |
| AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights | Press release | +0.66% | -6.77% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.66% | -6.77% | |
| Form 10-K AN2 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.62% | -4.74% | |
| AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights | Press release | +0.00% | — | |
| Form 10-Q AN2 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | — | |
| AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights | Press release | +0.47% | -0.94% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.47% | -0.94% | |
| AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights | Press release | +0.86% | +2.59% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.86% | +2.59% | |
| Form 10-K AN2 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -7.92% | +2.01% | |
| AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline | Press release | -3.17% | -2.91% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.17% | -2.91% | |
| AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights | Press release | +0.00% | -1.87% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -1.87% | |
| AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights | Press release | +0.00% | -2.99% | |
| Form 10-K/A AN2 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.99% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.99% | |
| Form 10-K AN2 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.76% | +10.26% | |
| AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights | Press release | +0.00% | -7.92% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -7.92% |
Keep exploring
More ANTX: analyst actions → · SEC filings → · ANTX overview →